Hatzimichael Eleftheria, Tuthill Mark
Department of Haematology, Medical School of Ioannina, University of Ioannina, Ioannina, Greece.
Stem Cells Cloning. 2010 Aug 26;3:105-17. doi: 10.2147/SCCAA.S6815.
More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell "rescue." Autologous HSCT is performed using the patient's own hematopoietic stem cells, which are harvested before transplantation and reinfused after myeloablation. Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. Survival after allogeneic transplantation depends on donor-recipient matching, the graft-versus-host response, and the development of a graft versus leukemia effect. This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications.
每年有超过25000例造血干细胞移植（HSCT）用于治疗淋巴瘤、白血病、免疫缺陷疾病、先天性代谢缺陷、血红蛋白病以及骨髓增生异常综合征和骨髓增殖性综合征。移植前，患者接受强化清髓性放化疗，随后进行干细胞“救援”。自体HSCT使用患者自身的造血干细胞，这些干细胞在移植前采集，清髓后再回输。异基因HSCT使用来自供体的人类白细胞抗原（HLA）匹配的干细胞。异基因移植后的生存取决于供体-受体匹配、移植物抗宿主反应以及移植物抗白血病效应的发展。本文综述了干细胞生物学、HSCT的临床疗效、移植程序以及潜在并发症。
